Advanced stages of classical Hodgkin lymphoma - first-line treatment options
Language English Country Czech Republic Media print
Document type Journal Article, Review
PubMed
34911330
DOI
10.48095/ccko2021450
PII: 129074
Knihovny.cz E-resources
- Keywords
- Chemotherapy, Hodgkin lymphoma, brentuximab vedotin, chemotherapy, nivolumab, pembrolizumab,
- MeSH
- Brentuximab Vedotin therapeutic use MeSH
- Hodgkin Disease diagnostic imaging drug therapy MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Immune Checkpoint Inhibitors therapeutic use MeSH
- Humans MeSH
- Nivolumab therapeutic use MeSH
- Positron-Emission Tomography MeSH
- Antineoplastic Agents therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Brentuximab Vedotin MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Immune Checkpoint Inhibitors MeSH
- Nivolumab MeSH
- pembrolizumab MeSH Browser
- Antineoplastic Agents MeSH
BACKGROUND: Advanced stages of classical Hodgkin lymphoma can be cured by the first-line treatment in 80% of patients. Conventional treatment options include ABVD chemotherapy (doxorubicin bleomycin, vinblastine, dacarbazine) or escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) are commonly used in advanced stages. The result of interim positron emission tomography allows adjustment of the treatment intensity during chemotherapy and this approach can affect the treatment results and toxicity. PURPOSE: This review summarizes current options of conventional chemotherapy and implementation of brentuximab vedotin and PD-1 inhibitors in combination with chemotherapy into the first-line treatment.
References provided by Crossref.org
